Inhibitor Therapeutics Reports $1.3 Million Net Loss and Liquidity Concerns in Q2 2026

Inhibitor Therapeutics, Inc. reported significant financial challenges in its latest 10-Q filing for the second quarter of 2026, revealing a net loss of $1.3 million, slightly higher than the $1.29 million loss recorded in the same period of 2025. The company has not generated any revenue during this period, maintaining a consistent trend from previous quarters. Total expenses for the first half of 2026 were approximately $1.31 million, a decrease from $1.37 million in the prior year, primarily due to reduced research and development costs. The company’s cash and cash equivalents have sharply declined to $515,758 as of June 30, 2026, down from $2.38 million at the end of 2025, raising concerns about its liquidity and ability to sustain operations.

The company’s balance sheet reflects a total stockholders’ deficit of $2.56 million, an increase from $1.29 million at the end of 2025. This deterioration is attributed to ongoing operational losses and a lack of revenue generation. Current liabilities have also decreased significantly to $174,894 from $766,330, largely due to a reduction in accrued expenses. However, the company continues to face challenges, including a pending $3 million securities purchase agreement with an institutional investor that has not yet been fulfilled, leading to litigation to recover the funds.

Strategically, Inhibitor Therapeutics is focused on the development of itraconazole for treating basal cell carcinoma nevus syndrome (BCCNS). The company has made notable progress in its clinical development strategy, including a change in the primary efficacy endpoint for its registration efforts with the FDA. This new endpoint focuses on the rate and response of surgically eligible basal cell carcinomas, a shift from the previously proposed per-lesion response rate. The FDA has acknowledged the company’s meeting request to discuss this new strategy, with written responses expected by the end of September 2026.

Operationally, the company has engaged Avior Bio, Inc. to develop a novel oral itraconazole formulation, which has shown promising pharmacokinetic profiles in preliminary studies. The company has also filed a provisional patent application for this formulation, aiming to secure intellectual property rights that could extend beyond the expiration of existing patents. Despite these advancements, the company’s employee headcount remains stable, and it continues to evaluate potential financing strategies to address its liquidity concerns.

Looking ahead, Inhibitor Therapeutics faces substantial uncertainty regarding its ability to continue as a going concern. The management is exploring various financing options, including public or private sales of equity or debt securities, to bolster its cash reserves. However, the outcome of these efforts remains uncertain, and the company has indicated that it may need to conduct additional clinical trials if the FDA does not agree with its proposed regulatory pathway. The ongoing litigation related to the securities purchase agreement adds another layer of complexity to its financial outlook.